SB939 is a histone deacetylase (HDAC) inhibitor that has shown potential in the treatment of various cancers. It works by altering gene expression, leading to the inhibition of tumor growth and the induction of cancer cell death. This compound has been studied in clinical trials for its efficacy in treating hematologic malignancies, such as lymphoma and leukemia, as well as solid tumors. Additionally, SB939 has demonstrated anti-angiogenic properties, which can help in reducing the blood supply to tumors, further inhibiting their growth. Its ability to modulate the immune response also makes it a candidate for combination therapies with other anticancer agents. Research continues to explore its full therapeutic potential and optimal use in cancer treatment regimens.